Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.58 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 2/20 | 0.49 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 4/20 | 0.42 |
| ▸ | MET | P08581 | 3/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30302532 | 0.90 | EGFR (0.58) | EGFRSYKPRKD1GRM4CYP1A2 | |
| SCHEMBL22803770 | 0.90 | EGFR (0.58) | EGFRSYKPRKD1GRM4CYP1A2 | |
| SCHEMBL22803859 | 0.82 | EGFR (0.51) | EGFRRETSYKPRKD1GRM4 | |
| SCHEMBL30302493 | 0.82 | EGFR (0.51) | EGFRRETSYKPRKD1GRM4 | |
| SCHEMBL22803860 | 0.81 | SYK (0.50) | EGFRRETSYKGRM4CYP1A2 | |
| SCHEMBL30302592 | 0.81 | SYK (0.50) | EGFRRETSYKGRM4CYP1A2 | |
| SCHEMBL30302544 | 0.80 | SYK (0.49) | EGFRRETSYKPRKD1GRM4 | |
| SCHEMBL22803847 | 0.80 | SYK (0.49) | EGFRRETSYKPRKD1GRM4 | |
| SCHEMBL22803685 | 0.78 | SYK (0.56) | EGFRRETSYKGRM4CYP1A2 | |
| SCHEMBL30302581 | 0.78 | SYK (0.56) | EGFRRETSYKGRM4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2023-04-06 | — | — | US | disclosed |
| US-20230092163-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-03-23 | — | — | US | disclosed |
| EP-3983383-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020257621-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020252240-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020252240-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230092163-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | EGFR 1391/4885RET 1978/4885SYK 748/4885 |
| US-20230106899-A1 | METHODS OF TREATING CANCER | STING1, CGAS, TBK1 | EGFR 2810/4885RET 752/4885SYK 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.